Curis (NASDAQ:CRIS – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect Curis to post earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Stock Performance
CRIS opened at $3.02 on Tuesday. The stock has a fifty day moving average of $3.30 and a 200-day moving average of $4.28. Curis has a fifty-two week low of $2.86 and a fifty-two week high of $17.49. The company has a market capitalization of $25.57 million, a P/E ratio of -0.39 and a beta of 3.41.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Curis in a report on Tuesday, December 10th.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Featured Articles
- Five stocks we like better than Curis
- Overbought Stocks Explained: Should You Trade Them?
- Confluent: How Data Streaming May Transform AI
- Most active stocks: Dollar volume vs share volume
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
